Carol Alexandrescu

Carol’s research career took various turns and pauses in places near and far, but she eventually joined the team at the Yale Center for XLH in 2015. Her role as the Center’s clinical trial coordinator for the adult phase 3 clinical trials of burosumab was instrumental in the drug’s approval. Her work with XLH and TIO patients continues to be rewarding and informative, and she contributes in large part to the disease monitoring programs for these disorders. Carol is committed to the ongoing research for XLH and other bone disorders in the hope of improving the lives of her patients.